Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) remains a highly aggressive subtype with limited treatment options and poor prognosis. While most therapies target tumor cells, the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), plays a key role in tumor progression, therapy resistance, and immune suppression. We developed NP-FAP-DOX, a mesoporous silica nanoparticle-based nanodevice loaded with doxorubicin and functionalized with a fibroblast activation protein alpha (FAP-α) ligand peptide for selective binding to FAP-α-positive CAFs. FAP-α targeting ability and cytotoxic effect were assessed in TNBC cells, patient-derived CAFs, and patient-derived organoids (PDOs). In vivo efficacy was evaluated in the murine orthotopic TNBC 4T1 allograft model, assessing tumor growth inhibition, toxicity, CAFs depletion, extracellular matrix degradation, apoptosis induction, and TME-associated cellular and stromal changes. NP-FAP-DOX exhibited controlled drug release, selective binding to FAP-α, and cytotoxicity in TNBC cells, patient-derived CAFs, and PDOs. In vivo, NP-FAP-DOX reduced tumor growth, depleted CAFs, degraded the extracellular matrix, induced apoptosis, increased lymphocyte infiltration, and decreased M2-like macrophages. Compared with free doxorubicin, NP-FAP-DOX enhanced therapeutic efficacy while reducing cardiotoxicity and systemic side effects. These findings highlight NP-FAP-DOX as a promising nanomedicine strategy for TNBC, integrating tumor inhibition, TME remodeling, and immune activation, with strong potential for clinical translation.
No takes yet. Share an insight, caveat, or question.
Lameirinhas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: